Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 2/20 | 0.31 |
| ▸ | USP14 | P54578 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140445 | 0.82 | ELANE (0.41) | ELANEGABRA1GABRA5L3MBTL1TSHR | |
| SCHEMBL20139756 | 0.80 | L3MBTL1 (0.51) | ELANEL3MBTL1PDE9A | |
| SCHEMBL20141852 | 0.74 | GRM2 (0.45) | L3MBTL1CYP11B1TSHRGRM2 | |
| SCHEMBL20140443 | 0.72 | ENPP2 (0.38) | GRIN1GRIN2BCYP11B1TSHRGRM2 | |
| SCHEMBL20139770 | 0.72 | PDE5A (0.37) | GRIN1GRIN2B | |
| SCHEMBL21787286 | 0.72 | RORC (0.33) | GABRA1GABRA5L3MBTL1GRIN1GRIN2B | |
| SCHEMBL20140201 | 0.70 | ESR1 (0.42) | ELANEL3MBTL1GRIN1GRIN2BTSHR | |
| SCHEMBL20161100 | 0.68 | GRIN1 (0.35) | GRIN1GRIN2B | |
| SCHEMBL20534347 | 0.66 | APP (0.48) | ELANEGABRA1GABRA5 | |
| SCHEMBL28253344 | 0.65 | ELANE (0.43) | ELANEGABRA1GABRA5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3538520-A2 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | ELANE 2411/4885GABRA1 1733/4885GABRA5 1755/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | ELANE 2419/4885GABRA1 1796/4885GABRA5 1863/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | ELANE 2419/4885GABRA1 1796/4885GABRA5 1863/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | ELANE 2411/4885GABRA1 1733/4885GABRA5 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.